目的 探討藥用炭片聯(lián)合碳酸鑭治療血液透析高磷血癥的臨床療效。方法 選取2014年5月—2016年5月在駐馬店市中心醫(yī)院治療的血液透析高磷血癥患者160例，隨機(jī)分為對(duì)照組（80例）和治療組（80例）。對(duì)照組口服碳酸鑭咀嚼片，1 g/次，3次/d；治療組在對(duì)照組基礎(chǔ)上口服藥用炭片，1.5 g/次，3次/d。兩組患者均經(jīng)過12周。觀察比較治療前后兩組患者臨床療效和血清學(xué)指標(biāo)。結(jié)果 治療后，對(duì)照組和治療組臨床總有效率分別為81.25%、93.75%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血磷、血鈣、血甲狀旁腺激素（PTH）、超敏C反應(yīng)蛋白（hs-CRP）、成纖維生長(zhǎng)因子23（FGF-23）和鈣磷乘積水平均明顯降低，同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組血清學(xué)指標(biāo)低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 藥用炭片聯(lián)合碳酸鑭治療血液透析高磷血癥可有效改善患者生存質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Medicinal Charcoal Tablets combined with lanthanum carbonate in treatment of hyperphosphatemia in hemodialysis. Methods Patients (160 cases) with hyperphosphatemia in hemodialysis in Zhumadian Central Hospital from May 2014 to May 2016 were randomly divided into control (80 cases) and treatment (80 cases) groups. Patients in the control group were po administered with Lanthanum Carbonate Chewable Tablets, 1 g/time, three times daily. Patients in the treatment group were po administered with Medicinal Charcoal Tablets on the basis of the control group, 1.5 g/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical efficacy and serological indexes were evaluated. Results After treatment, the clinical efficacy in the control and treatment groups were 81.25% and 93.75%, respectively, and there were differences between two groups (P < 0.05). After treatment, the blood phosphorus, blood calcium, PTH, hs-CRP, FGF-23, and calcium and phosphorus product levels in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And these serological indexes in the treatment group were more obviously lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Medicinal Charcoal Tablets combined with lanthanum carbonate can effectively improve the quality of life in treatment of hyperphosphatemia, which has a certain clinical application value.